Voyager Therapeutics, Inc.
VYGR
$3.77
-$0.18-4.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -45.73% | -82.42% | -66.83% | -93.03% | 433.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.73% | -82.42% | -66.83% | -93.03% | 433.79% |
| Cost of Revenue | 18.60% | -1.95% | 16.37% | 27.38% | 16.93% |
| Gross Profit | -300.94% | -1,000.67% | -230.69% | -141.25% | 73.59% |
| SG&A Expenses | -0.92% | 3.39% | 12.00% | -12.19% | -1.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.45% | -0.66% | 15.31% | 16.12% | 12.57% |
| Operating Income | -122.02% | -192.42% | -114.38% | -165.71% | 53.30% |
| Income Before Tax | -208.95% | -229.81% | -173.81% | -159.25% | 65.48% |
| Income Tax Expenses | 93.02% | -37.50% | 164.29% | -28.95% | 124.29% |
| Earnings from Continuing Operations | -208.40% | -229.18% | -173.80% | -161.15% | 65.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -208.40% | -229.18% | -173.80% | -161.15% | 65.08% |
| EBIT | -122.02% | -192.42% | -114.38% | -165.71% | 53.30% |
| EBITDA | -134.52% | -219.41% | -124.72% | -162.30% | 55.72% |
| EPS Basic | -203.45% | -223.85% | -167.94% | -146.40% | 73.53% |
| Normalized Basic EPS | -204.12% | -330.91% | -168.09% | -141.28% | 73.84% |
| EPS Diluted | -196.44% | -216.67% | -165.80% | -147.68% | 72.90% |
| Normalized Diluted EPS | -204.12% | -330.91% | -168.09% | -142.30% | 73.84% |
| Average Basic Shares Outstanding | 1.65% | 1.64% | 2.16% | 31.81% | 31.89% |
| Average Diluted Shares Outstanding | 1.65% | 1.64% | 2.16% | 28.61% | 31.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |